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Abstract
Factor XII (FXII) plays a pivotal role in hemostasis, inf lammation and complement system. Its deficiency is usually an
incidental finding in an otherwise asymptomatic patient who is identified during his/her routine preoperative blood work.
This study aimed in evaluating the clinical course of the surgical patients having FXII deficiency. Information regarding
demographics, laboratory tests and management of patients was obtained through medical chart and in-house integrated
laboratory management system whereas the medical literature was searched through PubMed® . During the study period,
two patients were consulted for FXII deficiency prior to the various surgical procedures. Both patients had uneventful
surgeries without any thrombotic events while hemorrhage observed in one patient was secondary to obstetric
complications. With the limited evidence today, it is concluded that patients having FXII deficiency are not at increased risk
of bleeding, thrombosis or infections during surgery, but a personalized approach is needed for planning an appropriate
perioperative management.

INTRODUCTION
Factor XII (FXII) is an important physiological mediator of
hemostasis, inflammation, complement system and fibrinolysis. Located on chromosome 5 with 13 exons, FXII gene encodes
for a single chain of 615 amino acids requiring post translational
modification for conversion to a mature 596-amino acid
zymogen in the liver [1]. Exposure to negatively charged surfaces
converts FXII to its active serine protease form FXIIa that triggers
factor XI activation, mediates inflammation by cleaving plasma
prekallikrein (PK) to its active kallikrein, activates C1r and
C1s of complement system, cleaves plasminogen to plasmin

during fibrinolysis [1] and activates neutrophil by interacting
with uPAR receptors [2]. FXII deficiency is a rare autosomal
recessive disorder with a frequency of 2.3% as reported in 300
healthy blood donors [3]. It is usually an incidental finding
during preoperative blood work in an otherwise asymptomatic
patient signifying dispensable role of FXII in intrinsic pathway
of secondary hemostasis. Interestingly, mutations in FXII gene
may lead to C1-inhibitor deficiency causing a rare disorder,
hereditary angioedema without concomitant FXII deficiency.
The current study described the perioperative clinical course of
two surgical patients having FXII deficiency and is anticipated
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Table 1: Demographics and laboratory details of the patients having FXII deficiency at presentation
Reference range

Proband 1

Proband 2

Age
Gender
Primary diagnosis
Hemoglobin g/dl

–
–
–
M 13.7–16.3
F 11.1–14.5
76–96
26–32
4–10
150–400
1–7
9.1–13.1
22.9–34.5
–
50–149
50–163
67–127
52–164
70–140
56–121
74–126
31–44
0.86–1.10
<10
<5

26
Female
Pregnancy
–
10.9
73.2
22.0
7.4
333
2.5
10.3
54.9
27.3
89
92
87
3
>150
48
103
31.7
0.99
4.72
0.87

35
Male
Oligo-dendro-glioma of brain
16.4
–
87.2
33.0
14
330
–
10
133.5
22.1
>200
140
123
<1
Not done
Not done
Not done
Not done
Not done
Not done
Not done

MCV fl
MCH pg/dl
White cell count X109 /L
Platelet Count X109 /L
Bleeding time minutes
PT seconds
APTT seconds
APTT mix 50:50 NP
FVIII %
FIX %
FXI %
FXII %
Protein C %
Protein S %
Antithrombin III %
lupus anticoagulant screen (RVVT) seconds
APCR
Anticardiolipin IgG GPL/ml
Anticardiolipin IgM MPL/ml

to assist clinicians in investigating and managing such patients;
most importantly to counsel the patient and the attending who
are worried for an unexpected bleeding or thrombosis during
surgery.

CASE REPORTS
First case was a 26-year-old multigravida (G4 P2 + 1 ) who presented at 18th week of gestation with a history of first trimesterfetal loss and postpartum hemorrhage in the last delivery. Her
physical examination was unremarkable. Laboratory work-up is
given in Table 1 that shows that she had FXII deficiency, low
protein S level and a negative lupus anticoagulant screen. At 35th
week of gestation, she had an emergency Caesarian-section with
an estimated blood loss of 1000 ml following surgical separation
of plastered uterus from anterior abdominal wall, dropping the
hemoglobin to 7.7 g/dl. Four units of fresh frozen plasma was
transfused during surgery while 1 gm intravenous tranexamic
acid was given thrice daily for 8 days. She also received thromboprophylaxis (40 mg enoxaparin subcutaneously) for surgical
procedure as per institutional protocol. Both mother and baby
were discharged in a stable condition after a week. The patient
showed an improvement of hemoglobin to 11.4 g/dl at threemonth follow-up.
Second case was a 35-year-male who presented with seizure
for few days. Computed tomography (CT) contrast showed right
frontal lobe parasagittal mass. Comorbidities included Graves’
disease for which he was receiving oral carbimazole. Hemostatic inquiry showed that patient had no personal or family
history of bleeding or thrombosis. He was previously operated
for incisional hernia and tonsillectomy; both of which were
uneventful. He was planned for surgical removal of the mass. His
preoperative work-up is detailed in Table 1 which shows that he
had FXII deficiency. The patient underwent uneventful surgery
without plasma or red cells transfusion.

DISCUSSION
The study described the clinical course of the two patients with
FXII deficiency having uneventful surgical procedures.
Prothrombin time (PT) and activated partial thromboplastin time (APTT) are the routine preoperative coagulation tests.
However, at least nine observational studies indicated a low
positive predictive value (0.03–0.22) and likelihood ratio (0.94–
5.1) for these coagulation tests for predicting surgical bleeding
[4]. This may not be the case if a surgery itself is associated
with a high hemorrhagic risk and where it is important to
identify obscure bleeding tendency in a surgical patient having prolonged PT/APTT. A reasonable testing algorithm for prolonged PT/APTT includes the exclusion of preanalytic variables
like high hematocrit, incompletely filled tube, icteric, lipemic or
hemolyzed sample followed by obtaining clinical details such
as a history of thrombosis, bleeding or an intake of anticoagulants and or the presence of systemic disease. The test is then
repeated following an addition of normal pooled plasma (NP)
in a 50:50 ratio. Although a correction of clotting time implies
deficiency of clotting factors, the presence of inhibiting factors
(like lupus anticoagulant or anticardiolipin antibodies) will keep
the initial test result unchanged. For an isolated prolonged APTT
that shows correction with NP, the final step is to perform factors
VIII, IX, XI and XII assays and if possible, high molecular weight
kininogen (HK) and PK.
FXII deficiency is usually found accidentally on routine coagulation screening prior to surgery in an asymptomatic patient. In
a study on 8069 planned surgical patients, prolonged APTT was
observed in 5.8% patients primarily due to anticoagulants usage
while FXII deficiency was observed in only three of 17 patients
tested for FXII assay [5]. In contrast, acquired FXII deficiency
is frequent as reported by Bachler M et al. in 51% of his 79
critically ill intensive care patients having sepsis, renal failure
and following blood transfusion [6].
The two patients with FXII deficiency in this case report
underwent successful surgical procedures without any
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thrombotic events during or after surgery. Patient 1 had subnormal protein S which is a usual finding in a normal pregnancy
because of its increase binding to protein C4b. Her lupus
anticoagulant screening was negative and therefore cannot be
accounted for her single fetal loss. There was no perioperative
bleeding in Patient 2 while excessive bleeding observed in
Patient 1 was secondary to underlying obstetric complication
and responded to the administration of tranexamic acid, an
antifibrinolytic agent that is commonly used in treating obstetric
hemorrhage. It is difficult to justify the transfusion decision in
Patient 1; perhaps obstetrician aimed to control bleeding with
normalization of APTT.
Interestingly, FXII was named after John Hageman, a 37-yearold male who was the first patient identified with FXII (Hageman factor) deficiency and died of pulmonary embolism (PE)
following surgery for fractured hemipelvis [7] which might be a
consequence of his postoperative immobilization unrelated to
deficiency of FXII [7]. Girolami et al. in 2004 reviewed 24 surgical
patients with inherited FXII deficiency [8] and none had any
significant postoperative hemorrhage or thrombosis except for
one patient who bled during nasal polypectomy. Surprisingly,
33% of the patients received whole blood and plasma therapy
prior to surgery [8] without evidence for this need. Cardiac
bypass surgery is a major challenge for hemostasis and is a good
model for evaluating hemorrhagic or thrombotic potential in
surgical patients. No bleeding or thrombotic complication was
observed postoperatively in any patients having FXII deficiency
who had bypass surgeries [9]. In such patients, heparin monitoring is daunting due to prolonged activated clotting time or
APTT that can now be tested through heparin concentration
or anti-Xa assay. FXII plays a role in neutrophil chemotaxis
and activation of classical complement pathway, so individuals
with low levels of FXII are theoretically at increased risk of
infections with encapsulated organism. One patient with FXII
deficiency so far was described having wound infection with
Escerichia coli [10].
Though prolonged APTT secondary to FXII deficiency is well
known to the hematologists but this may not be the case with
surgeons, fellows and residents who deal with perioperative
coagulopathy with a general tendency to transfuse plasma for
correcting prolonged clotting times. These two cases highlighted
the significance of hematology consultation with appropriate
surgical plan for patients with FXII deficiency with personalized approach. Larger case series are required for an evidencebased approach but given the rarity of the disorder, this task is
apparently difficult to achieve.

